These findings demonstrate that SEVs have a role in cancer development and suggest that targeting the release of ANGPTL2-SEVs from endothelial cells would be an effective strategy in the treatment of some types of AML[134]. The gene discussed is ANGPTL2; the disease is acute myeloid leukemia.